9 completed, 8 terminated, 5 recruiting, 5 unknown. 33 Phase 2, 9 Phase 1, 1 Phase 3.
Follow Hepatocellular Cancer: new trials by email Literature Review of Hepatocellular Cancer trials Research Report on Hepatocellular Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma BGB-B2033 - Hepatocellular Cancer, Liver Cancer | Phase 2 | Not yet recruiting | BeOne Medicines | 100 | 2026-11-30 | 2026-11-03 |
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. PF-08634404, Ipilimumab - Carcinoma, Hepatocellular, Hepatocellular Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 138 | 2025-12-01 | 2026-10-08 |
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies KRAS TCR-Transduced PBL, Aldesleukin, Fludarabine - Gastrointestinal Carcinoma, Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer SHR-1826, SHR-1826 and immunotherapy combination therapy - Hepatocellular Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 53 | 2025-05-01 | 2025-04-20 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) Durvalumab, Gemcitabine, Nab paclitaxel - Pancreatic Cancer, Hepatocellular Cancer | Phase 2 | Active not recruiting | AHS Cancer Control Alberta | 15 | 2023-07-05 | 2026-11-04 |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors Q702, Pembrolizumab - Esophageal Cancer, Gastric Cancer | Phase 1 / Phase 2 | Active not recruiting | Qurient Co., Ltd. | 120 | 2023-01-12 | 2026-02-24 |
| Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 2 | Recruiting | Asan Medical Center | 138 | 2022-10-22 | 2025-02-21 |
| A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two - Hepatocellular Carcinoma, Solid Tumor | Phase 1 / Phase 2 | Terminated | Omega Therapeutics | 24 | 2022-08-19 | 2025-02-03 |
| Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib Anlotinib;Toripalimab - Hepatocellular Cancer | Phase 2 | Unknown | Shen Feng | 30 | 2022-07-08 | 2022-07-12 |
| A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors TAK-500, Pembrolizumab, Tocilizumab - Pancreatic Cancer, Hepatocellular Cancer | Phase 1 / Phase 2 | Terminated | Takeda | 61 | 2022-04-14 | 2026-01-22 |
| Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC Neoantigen Dendritic Cell Vaccine, Nivolumab - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 2 | Recruiting | National Cancer Centre, Singapore | 60 | 2021-04-15 | 2026-07-31 |
| Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma durvalumab, Doxorubicin-Eluting Beads, TACE - Hepatocellular Cancer, Hepatocellular Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 27 | 2021-03-10 | 2026-10-26 |
| High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors Vitamin C, Metformin - Hepatocellular Cancer, Pancreatic Cancer | Phase 2 | Unknown | Zhongnan Hospital | 30 | 2020-07-01 | 2023-09-28 |
| A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion hepatic resection, Sorafenib - Hepatocellular Cancer | Phase 2 | Unknown | White Plains Hospital | 200 | 2019-09-06 | 2021-04-14 |
| Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers nivolumab, tadalafil, oral vancomycin - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 22 | 2019-06-05 | 2026-02-23 |
| Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma Nivolumab, TACE - Carcinoma, Hepatocellular, Hepatic Carcinoma | Phase 2 | Completed | AIO-Studien-gGmbH | 49 | 2018-06-14 | 2023-07-20 |
| Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine - Melanoma, Colon Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2018-05-18 | 2020-06-02 |
| Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR) Trans-arterial Chemo-Embolization, Doxorubicin, Stereotactic Ablative Radiotherapy - Liver Neoplasms, Hepatocellular Cancer | Phase 2 | Terminated | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 3 | 2017-02-20 | 2017-11-07 |
Showing 20 of 33. Sign in to see all of them.
Liver Neoplasms (33) · Carcinoma, Hepatocellular (10) · Pancreatic Neoplasms (8) · Colorectal Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Stomach Neoplasms (5) · Cholangiocarcinoma (4) · Breast Neoplasms (3) · Colonic Neoplasms (3) · Esophageal Neoplasms (3) · Kidney Neoplasms (3) · Melanoma (3) · Neoplasm Metastasis (3) · Biliary Tract Neoplasms (2) · Carcinoma, Renal Cell (2)
Digestive System Diseases (33) · Digestive System Neoplasms (33) · Liver Diseases (33) · Neoplasms by Site (33) · Neoplasms (32) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (16) · Adenocarcinoma (15) · Carcinoma (15) · Gastrointestinal Diseases (11) · Gastrointestinal Neoplasms (10) · Colonic Diseases (9) · Intestinal Diseases (9) · Intestinal Neoplasms (9) · Endocrine Gland Neoplasms (8)
Nivolumab (4) · Sorafenib (4) · Bevacizumab (2) · Cyclophosphamide (2) · Ipilimumab (2) · Oxaliplatin (2) · aldesleukin (2) · durvalumab (2) · fludarabine (2) · pembrolizumab (2) · tremelimumab (2) · Albumin-Bound Paclitaxel (1) · Ascorbic Acid (1) · Capecitabine (1) · Cisplatin (1)
National Cancer Institute (NCI) (6) · 7 Hills Pharma, LLC (1) · AHS Cancer Control Alberta (1) · AIO-Studien-gGmbH (1) · Asan Medical Center (1) · BeOne Medicines (1) · Beth Israel Deaconess Medical Center (1) · City of Hope Medical Center (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Eli Lilly and Company (1) · Emory University (1) · Massachusetts General Hospital (1) · ModeX Therapeutics, An OPKO Health Company (1) · National Cancer Centre, Singapore (1) · Omega Therapeutics (1)
United States (21) · China (5) · South Korea (3) · Singapore (2) · Taiwan (2) · Belgium (1) · Canada (1) · Germany (1) · Hong Kong (1) · Japan (1) · Nepal (1) · Puerto Rico (1) · Switzerland (1)
Tim F Greten, M.D. (3) · Steven A Rosenberg, M.D. (2) · Andrea Bullock, MD, MPH (1) · Arndt Vogel, Prof.Dr. (1) · Bassel El-Rayes, MD (1) · Bikal Ghimire, MS (1) · Fuxiang Zhou, M.D (1) · Ju Hyun Shim (1) · Kyle Cuneo, MD (1) · Lionel Lewis, MA, MB.Bch, MD (1) · Lipika Goyal, MD (1)
PMID 10400410, PMID 11413430, PMID 15273542, PMID 1598671, PMID 16810012, PMID 17005947, PMID 17538089, PMID 17943760, PMID 19011538, PMID 19638912, PMID 19770617, PMID 20554319, PMID 22012809, PMID 27756258, PMID 28796864, PMID 32557715, PMID 33016924, PMID 34155211, PMID 34297268, PMID 41495607, PMID 8607670
2017 (1), 2025 (1), K23CA139005 (1)